Flerie is an active long-term life-science investor focused on biotech and pharmaceutical companies as well as related tools and services. Rather than running its own drug pipeline as a traditional biotech, it builds and supports a portfolio of product-development and commercial-growth businesses. Its model targets investors seeking exposure to drug development and enabling technologies through a listed investment vehicle.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -251.1 | — |
| Q2 2025 | 8.7 | — | 173.5 | — |
| Q4 2025 | 0.6 | — | -541 | — |
| Q1 2026 | 0 | — | -61.5 | — |
| Q2 2026 | 1.3 | -85.1% | -92.4 | -153.3% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: BICO Group AB (publ) (BICO), Midsona AB (publ) (MSON B), Byggmästare Anders J Ahlström Holding AB (publ) (AJA B), Cheffelo AB (publ) (CHEF), Logistri Fastighets AB (publ) (LOGIST A), Bulten AB (publ) (BULTEN)